A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial - Trial NCT06301308
Access comprehensive clinical trial information for NCT06301308 through Pure Global AI's free database. This Phase 3 trial is sponsored by Second Xiangya Hospital of Central South University and is currently Withdrawn. The study focuses on Bladder Cancer. Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Second Xiangya Hospital of Central South University
Timeline & Enrollment
Phase 3
Oct 01, 2023
Feb 29, 2024
Primary Outcome
Access the pain score using the Visual Analogue Scale (VAS)
Summary
The goal of this clinical trial is to learn about a novel application of lidocaine injection
 in male patients who needs rigid cycstoscopy test. The main question it aims to answer
 is:Does New Application of Lidocaine Liquid Provide Pain Relief for Patients During
 Cystoscopy? Before the cycstoscopy,Participants will be randomly divided into three different
 anesthesia mode groups,namely are Group A (intraurethral lidocaine gel alone), Group B
 (intraurethral lidocaine gel + lidocaine 2% injection), and Group C (intraurethral lidocaine
 gel + liquid paraffinl).Patients only need to prepare and cooperate according to routine
 surgical operations๏ผwhich is group B or group C.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06301308
Non-Device Trial